No Data
BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years
Earnings Scheduled For May 14, 2025
BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.
In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.
Earnings Preview: BeiGene
Crude Oil Gains 3%; US Inflation Eases In April
12 Health Care Stocks Moving In Tuesday's Intraday Session
lightfoot : junk, hook, line and sinker
Wonder-Man : great post. thank you for sharing
Christopher Flint197 : like to learn what a swing trade looks like and when to get in and out.